In all, our findings show how metformin and CR could be taken into consideration to improve the therapeutic response of a particular subgroup of NSCLC patients who lack LKB1, exploiting the inability of these tumors to overcome metabolic stress. The gene discussed is STK11; the disease is non-small cell lung carcinoma.